

Message

**From:** Larry Kier [ldkier@[REDACTED]]  
**Sent:** 1/28/2013 6:02:30 PM  
**To:** 'Sheppard, Bridget' [REDACTED@informa.com]; 'Roger McClellan' [REDACTED@att.net]  
**CC:** 'Duncan, Lindsay' [REDACTED@informa.com]; 'Mildred Morgan' [REDACTED@hargray.com]  
**Subject:** RE: Critical Reviews in Toxicology - Decision on Manuscript ID BTXC-2012-0065.R1

Thanks again.

I hope the CATS system is user friendly like what I have encountered so far from the website.

Larry Kier

**From:** Sheppard, Bridget [mailto:[REDACTED]@informa.com]  
**Sent:** Monday, January 28, 2013 10:23 AM  
**To:** Larry Kier; Roger McClellan  
**Cc:** Duncan, Lindsay; Mildred Morgan  
**Subject:** RE: Critical Reviews in Toxicology - Decision on Manuscript ID BTXC-2012-0065.R1

Dear Larry Kier,

Thank you for your email.


Your article is now in Production and is currently being typeset. You should receive proofs of your article Feb 8<sup>th</sup>, you will then be able submit corrections to your article using our CATS system. An email explaining this process will be sent along with the proofs of your article.

If you have any other queries please let me know.

Kind Regards,

Bridget Sheppard  
Managing Editor  
Informa Healthcare  
119 Farringdon Road | London | EC1R 3DA | UK

Tel: +[REDACTED]  
email: [REDACTED]@informa.com



**From:** Larry Kier [mailto:ldkier@ ]  
**Sent:** 24 January 2013 23:36  
**To:** 'Roger McClellan'; Sheppard, Bridget  
**Cc:** Duncan, Lindsay; 'Mildred Morgan'  
**Subject:** RE: Critical Reviews in Toxicology - Decision on Manuscript ID BTXC-2012-0065.R1

Roger and Bridget,

Thank everyone very much for your positive decision. That's good news indeed.

Today, being a perfectionist, I have been re-reviewing the manuscript, and have found a few very minor errors that should be corrected and a few extraneous sentences that should be removed because they are somewhat confusing and have completely unnecessary detail so deletion would be preferable to wordsmithing.

I would please like to know what the best approach will be to have these changes incorporated into the paper. I'm not sure what process is being used to convert from Word markup or what will work best for this process. I can upload a revision mark-up with these changes added to the website or I can send a version with only these changes marked.

Just let me know what works best for the process and I will accommodate any request tomorrow so there shouldn't be any undue delay.

I believe there will definitely be interest in open access.

Thanks again for the good news.

Larry Kier

**From:** Roger McClellan [mailto: @att.net]  
**Sent:** Thursday, January 24, 2013 10:36 AM  
**To:** Bridget Sheppard  
**Cc:** Lindsay Duncan; Mildred Morgan; Roger O. McClellan; Larry Kier  
**Subject:** Fw: Critical Reviews in Toxicology - Decision on Manuscript ID BTXC-2012-0065.R1

Bridget:

It will be appropriate to attempt to publicize this paper when it is released. This is a widely used agricultural chemical that is extraordinarily important in commerce. I can not think of any other agricultural chemical whose use has greater impact. Let me know what the options are and what I and the authors can do to assist you.

Regards,  
Roger

----- Forwarded Message -----

**From:** "roger.o.mcclellan@ " <roger.o.mcclellan >  
**To:** ldkier@  
**Cc:** mbmorgan ; roger.o.mcclellan  
**Sent:** Thu, January 24, 2013 10:05:40 AM  
**Subject:** Critical Reviews in Toxicology - Decision on Manuscript ID BTXC-2012-0065.R1

24-Jan-2013

Dear Dr Kier:

Ref: Review of Genotoxicity Studies of Glyphosate and Glyphosate-Based Formulations

I was pleased to receive your revised manuscript and, especially, to note the careful attention you gave the reviewer's comments. As a result, it is my opinion, that the revised manuscript is improved and will be viewed as the definitive review on the genotoxicity of the important compound. Thus, I am pleased to accept your paper in its current form which will now be forwarded to the publisher for copy editing and typesetting.

You will receive proofs for checking, and instructions for transfer of copyright in due course.

The publisher also requests that proofs are checked and returned within 48 hours of receipt.

During the production process you will be given the opportunity to purchase "open access" for your paper. I urge you to take advantage of this opportunity. With "open access" available you will be able to call the paper to the attention of your colleagues and other interested parties and they can download the article at no cost to them. The availability of "open access" typically increases readership and future reference to the paper.

Thank you for your contribution to Critical Reviews in Toxicology and we look forward to receiving further submissions from you.

Sincerely,

Roger O. McClellan  
Editor-in-Chief, Critical Reviews in Toxicology  
[roger.o.mcclellan@informa.com](mailto:roger.o.mcclellan@informa.com)

Visit [www.informapharmascience.com](http://www.informapharmascience.com) and sign up for free eTOC alerts to all Informa Pharmaceutical Science journals

---

The information contained in this email message may be confidential. If you are not the intended recipient, any use, interference with, disclosure or copying of this material is unauthorised and prohibited. Although this message and any attachments are believed to be free of viruses, no responsibility is accepted by Informa for any loss or damage arising in any way from receipt or use thereof. Messages to and from the company are monitored for operational reasons and in accordance with lawful business practices.

If you have received this message in error, please notify us by return and delete the message and any attachments. Further enquiries/returns can be sent to [postmaster@informa.com](mailto:postmaster@informa.com)